← Leaderboards
Robert S Brown
University Of North Carolina Chapel Hill
$3,426,728
Attributed
$4,861,698
Total exposure
5
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $763.4K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,861,698 · 5
By mechanism
U01$4,090,058 · 2
M01$771,640 · 3
Top collaborators
- Elizabeth Clarice Verna7 shared
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Kim L Brouwer$15,343,248
- M Patricia Rivera$1,218,276
- Michael J Fried$0
- Lloyd J Edwards$5,857,462
- Craig R Lee$5,134,981
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsMicroorganism Disease ChemotherapyHuman SubjectHuman Therapy EvaluationChronic Disease /DisorderHepatitis CCombination ChemotherapyRibavirinHepatitis C VirusBehavioralData SetCessation Of LifeDisorder RiskChronic Liver InjuryEffectivenessClinical Trials DesignClinical PredictorsComplexCryptogenic CirrhosisBiomarker DiscoveryClinically RelevantClinical DataCohortBiological Markers
Grant awards (26)
Strategies and Therapies for Outcomes Prevention in Cirrhosis: The STOP-C Liver Cirrhosis Network$417,897
U01 · FY2025 · DK · contact PI
Strategies and Therapies for Outcomes Prevention in Cirrhosis: The STOP-C Liver Cirrhosis Network$419,793
U01 · FY2024 · DK · contact PI
Strategies and Therapies for Outcomes Prevention in Cirrhosis: The STOP-C Liver Cirrhosis Network$292,750
U01 · FY2024 · DK · contact PI
Strategies and Therapies for Outcomes Prevention in Cirrhosis: The STOP-C Liver Cirrhosis Network$622,831
U01 · FY2023 · DK · contact PI
Strategies and Therapies for Outcomes Prevention in Cirrhosis: The STOP-C Liver Cirrhosis Network$574,395
U01 · FY2022 · DK · contact PI
Strategies and Therapies for Outcomes Prevention in Cirrhosis: The STOP-C Liver Cirrhosis Network$189,021
U01 · FY2022 · DK · contact PI
Strategies and Therapies for Outcomes Prevention in Cirrhosis: The STOP-C Liver Cirrhosis Network$353,253
U01 · FY2021 · DK · contact PI
Race &Viral Resistance in Chronic Hepatitis C (VIRAHEP*$100,000
U01 · FY2005 · DK
Race &Viral Resistance in Chronic Hepatitis C (VIRAHEP*$160,000
U01 · FY2004 · DK
Race &Viral Resistance in Chronic Hepatitis C (VIRAHEP*$350,000
U01 · FY2003 · DK
Race &Viral Resistance in Chronic Hepatitis C (VIRAHEP*$370,000
U01 · FY2002 · DK
PEB IFN AND RIBAVIRIN VERSUS REBETRON IN HEPATITIS C$192,910
M01 · FY2002 · RR
ADEFOVIR DIPIVOXIL FOR PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION$192,910
M01 · FY2002 · RR
Race &Viral Resistance in Chronic Hepatitis C (VIRAHEP*$240,118
U01 · FY2001 · DK
PEB IFN AND RIBAVIRIN VERSUS REBETRON IN HEPATITIS C$192,910
M01 · FY2001 · RR
ADEFOVIR DIPIVOXIL FOR PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION$192,910
M01 · FY2001 · RR
PEB IFN AND RIBAVIRIN VERSUS REBETRON IN HEPATITIS C$0
M01 · FY2001 · RR
ADEFOVIR DIPIVOXIL FOR PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION$0
M01 · FY2001 · RR
PEB IFN AND RIBAVIRIN VERSUS REBETRON IN HEPATITIS C$0
M01 · FY2000 · RR
INTRON A &RIBAVIRIN COMBINATION IN CHRONIC HEPATITIS C$0
M01 · FY2000 · RR
INTRON A &RIBAVIRIN COMBINATION IN CHRONIC HEPATITIS C$0
M01 · FY2000 · RR
ADEFOVIR DIPIVOXIL FOR PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION$0
M01 · FY2000 · RR
INTRON A &RIBAVIRIN COMBINATION IN CHRONIC HEPATITIS C$0
M01 · FY2000 · RR
INTRON A &RIBAVIRIN COMBINATION IN CHRONIC HEPATITIS C$0
M01 · FY2000 · RR
ADEFOVIR DIPIVOXIL FOR PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION$0
M01 · FY2000 · RR
PEB IFN AND RIBAVIRIN VERSUS REBETRON IN HEPATITIS C$0
M01 · FY2000 · RR